Cardiac calcium handling on trial: targeting the failing cardiomyocyte signalosome.
作者信息
Pleger Sven T, Raake Philip, Katus Hugo A, Most Patrick
机构信息
From the Molecular and Translational Cardiology, Department of Internal Medicine III (S.T.P., P.R., H.A.K., P.M.), DZHK (German Center for Cardiovascular Research), Partner site Heidelberg/Mannheim (H.A.K., P.M.), Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany; and Center for Translational Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, PA (P.M.).
出版信息
Circ Res. 2014 Jan 3;114(1):12-4. doi: 10.1161/CIRCRESAHA.113.302748.
Abstract
摘要
相似文献
1
Cardiac calcium handling on trial: targeting the failing cardiomyocyte signalosome.心脏钙处理的试验：靶向衰竭心肌细胞信号体
Circ Res. 2014 Jan 3;114(1):12-4. doi: 10.1161/CIRCRESAHA.113.302748.
2
MicroRNA therapy for the failing heart.用于衰竭心脏的微小RNA疗法。
Circ Cardiovasc Genet. 2014 Jun;7(3):393-4. doi: 10.1161/CIRCGENETICS.114.000687.
3
Sarcoendoplasmic reticulum calcium transport ATPase 2a: a potential gene therapy target in heart failure.肌浆内质网钙转运 ATP 酶 2a：心力衰竭的潜在基因治疗靶点。
Cardiol Rev. 2013 May-Jun;21(3):151-4. doi: 10.1097/CRD.0b013e3182749cdb.
4
Targeting sarcoplasmic reticulum calcium ATPase by gene therapy.通过基因治疗靶向肌浆网钙 ATP 酶。
Hum Gene Ther. 2013 Nov;24(11):937-47. doi: 10.1089/hum.2013.2512.
5
Targeted sarcoplasmic reticulum Ca2+ ATPase 2a gene delivery to restore electrical stability in the failing heart.靶向肌浆网 Ca2+-ATP 酶 2a 基因转导恢复衰竭心脏的电稳定性。
Circulation. 2012 Oct 23;126(17):2095-104. doi: 10.1161/CIRCULATIONAHA.111.071480. Epub 2012 Sep 27.
6
Sarcoplasmic reticulum and calcium cycling targeting by gene therapy.基因治疗靶向肌浆网和钙循环。
Gene Ther. 2012 Jun;19(6):596-9. doi: 10.1038/gt.2012.34. Epub 2012 May 17.
7
Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure.经皮基因治疗增强心肌钙（CUPID）：晚期心力衰竭患者冠状动脉内肌浆网 Ca2+-ATP 酶基因治疗的 2 期试验。
Circulation. 2011 Jul 19;124(3):304-13. doi: 10.1161/CIRCULATIONAHA.111.022889. Epub 2011 Jun 27.
8
Heartening results: the CUPID gene therapy trial for heart failure.振奋人心的结果：心力衰竭的CUPID基因治疗试验。
Mol Ther. 2011 Jul;19(7):1181-2. doi: 10.1038/mt.2011.123.
9
Gene therapy for heart failure: an investigational treatment that is coming of age.心力衰竭的基因治疗：一种日趋成熟的试验性治疗方法。
Rev Esp Cardiol. 2010 Feb;63(2):137-40. doi: 10.1016/s1885-5857(10)70030-x.
10
Cardiac gene therapy with SERCA2a: from bench to bedside.心脏基因治疗中的 SERCA2a：从实验室到临床。
J Mol Cell Cardiol. 2011 May;50(5):803-12. doi: 10.1016/j.yjmcc.2010.11.011. Epub 2010 Nov 18.
引用本文的文献
1
Gene Therapy for Cardiovascular Disease: Clinical Perspectives.心血管疾病的基因治疗：临床视角。
Yonsei Med J. 2024 Oct;65(10):557-571. doi: 10.3349/ymj.2024.0127.
2
Raf kinase inhibitor protein: lessons of a better way for β-adrenergic receptor activation in the heart.Raf激酶抑制蛋白：心脏中β-肾上腺素能受体激活的更佳方式的启示
J Physiol. 2017 Jun 15;595(12):4073-4087. doi: 10.1113/JP274064. Epub 2017 May 23.
3
Inhibition of cardiac CaMKII to cure heart failure: step by step towards translation?抑制心脏钙调蛋白依赖性蛋白激酶II治疗心力衰竭：向临床转化逐步迈进？
Basic Res Cardiol. 2016 Nov;111(6):66. doi: 10.1007/s00395-016-0582-1. Epub 2016 Sep 28.
4
Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation.心血管疾病的基因治疗：载体开发、靶向及临床转化递送方面的进展
Cardiovasc Res. 2015 Oct 1;108(1):4-20. doi: 10.1093/cvr/cvv205. Epub 2015 Aug 3.
本文引用的文献
1
Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality.AAV1/SERCA2a 基因转导治疗严重心力衰竭患者的长期疗效：心血管事件再发和死亡率分析。
Circ Res. 2014 Jan 3;114(1):101-8. doi: 10.1161/CIRCRESAHA.113.302421. Epub 2013 Sep 24.
2
Heart failure gene therapy: the path to clinical practice.心力衰竭基因治疗：走向临床实践的道路。
Circ Res. 2013 Aug 30;113(6):792-809. doi: 10.1161/CIRCRESAHA.113.300269.
3
Immune responses to AAV vectors: overcoming barriers to successful gene therapy.腺相关病毒载体的免疫反应：克服成功基因治疗的障碍。
Blood. 2013 Jul 4;122(1):23-36. doi: 10.1182/blood-2013-01-306647. Epub 2013 Apr 17.
4
Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure.经皮基因治疗增强心肌钙（CUPID）：晚期心力衰竭患者冠状动脉内肌浆网 Ca2+-ATP 酶基因治疗的 2 期试验。
Circulation. 2011 Jul 19;124(3):304-13. doi: 10.1161/CIRCULATIONAHA.111.022889. Epub 2011 Jun 27.
5
The complex and evolving story of T cell activation to AAV vector-encoded transgene products.T 细胞对 AAV 载体编码的转基因产物激活的复杂而演变的故事。
Mol Ther. 2011 Jan;19(1):16-27. doi: 10.1038/mt.2010.250. Epub 2010 Nov 30.
6
Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection.全身注射后1-9型腺相关病毒血清型介导的基因表达及嗜性在小鼠中的分析
Mol Ther. 2008 Jun;16(6):1073-80. doi: 10.1038/mt.2008.76. Epub 2008 Apr 15.
7
Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure.在心力衰竭临床前模型中，通过基因转移长期表达肌浆网钙ATP酶2a后心脏功能障碍的逆转。
J Am Coll Cardiol. 2008 Mar 18;51(11):1112-9. doi: 10.1016/j.jacc.2007.12.014.
8
Calcium cycling and signaling in cardiac myocytes.心肌细胞中的钙循环与信号传导。
Annu Rev Physiol. 2008;70:23-49. doi: 10.1146/annurev.physiol.70.113006.100455.
9
AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice.携带肝脏特异性启动子的腺相关病毒2型载体可促进治疗水平的α-半乳糖苷酶A的持续表达，并诱导法布里病小鼠产生免疫耐受。
Mol Ther. 2004 Feb;9(2):231-40. doi: 10.1016/j.ymthe.2003.11.015.
10
Calcium signalling: dynamics, homeostasis and remodelling.钙信号传导：动力学、稳态与重塑
Nat Rev Mol Cell Biol. 2003 Jul;4(7):517-29. doi: 10.1038/nrm1155.
Zotero 插件